CSIMarket


Vistagen Therapeutics Inc   (VTGN)
Other Ticker:  
 


 

Vistagen Therapeutics Inc

VTGN's Financial Statements and Analysis



Vistagen Therapeutics Inc narrowed forth quarter of 2024 net loss per share of $-0.18 compare to net loss per share of $-1.71 recorded in the same quarter a year ago and improved compare to net loss per share of $-0.22 realized in previous quarter.


forth quarter of 2024
Earnings Per Share Revenues
$ -0.18 $  0 Mill
$+1.53     $+1M    



Vistagen Therapeutics Inc 's Revenue rose by -220.9 % in forth quarter of 2024 (Mar 31 2024) year on year, to $0 million and declined by -8.87 % sequentially.


Vistagen Therapeutics Inc is

More on VTGN's Income Statement



Vistagen Therapeutics Inc in the forth quarter of 2024 recorded net loss of $-9.521 million, an improvement compare to net loss of $-12.227 million in IV. Quarter a year ago.

Sequentially net loss advanced

More on VTGN's Growth

Vistagen Therapeutics Inc Inventories
In Mar 31 2024 company's net cash and cash equivalents decreased by $-7 million


Vistagen Therapeutics Inc does not pay out common stock dividend.

In trailing twelve-month period Vistagen Therapeutics Inc payed $ -1.34 cash per share, on a free-cash flow basis .

Book value grew by 41.03 % sequentially to $5.92 per share.
Tangible Book value grew to $ 5.92 per share from $ 4.20.

Company repurchased 10.07 million shares or 34.27 % in Mar 31 2024.


More on VTGN's Dividends

 Market Capitalization (Millions) 68
 Shares Outstanding (Millions) 19
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) 1
 Net Income (TTM) (Millions $) -29
 Cash Flow (TTM) (Millions $) 103
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -




Vistagen Therapeutics Inc does not pay out common stock dividend.

In trailing twelve-month period Vistagen Therapeutics Inc had negative $ -1.34 cash flow per share, on a free-cash flow basis .

Book value grew by 41.03 % sequentially to $5.92 per share.
Tangible Book value grew to $ 5.92 per share from $ 4.20.

Company repurchased 10.07 million shares or 34.27 % in Mar 31 2024.


More on VTGN's Balance Sheets

 Market Capitalization (Millions) 68
 Shares Outstanding (Millions) 19
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) 1
 Net Income (TTM) (Millions $) -29
 Cash Flow (TTM) (Millions $) 103
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -
   


  News about Vistagen Therapeutics Inc Earnings

Vistagen Therapeutics Inc Shows Strong Financial Improvement in First Quarter of Fiscal Year 2024

The financial results of Vistagen Therapeutics Inc for the fiscal year ended March 31, 2024, show a notable improvement in key metrics compared to the previous year. The company managed to decrease its loss per share from $-1.71 to $-0.18, signaling a positive trend towards profitability. Additionally, revenue declined by -8.872%, but this was offset by an improvement in earnings per share from $-0.22 to $-0.18.
Furthermore, Vistagen Therapeutics Inc reported a net deficit of $-9.521 million for the January to March 31, 2024, period, compared to a deficit of $-12.227 million in the same period the previous year. The company also noted a net deficit of $-29.36 million for the fiscal year 2024, alongside r...

Revolutionizing the Treatment Landscape: How Vistagen Therapeutics Inc is Transforming Mental Health Care

In an exciting turn of events, Vistagen Therapeutics Inc has revealed impressive revenue figures of $0.4114 million in their third quarter of the 2024 earnings season. This marks a significant improvement for the company compared to the same period last year when they reported a deficit of $-9.761 million. This positive revenue growth is a testament to Vistagen's dedication and innovation in the field of neuroscience.
Vistagen Therapeutics Inc, a late clinical-stage biopharmaceutical company, is making waves in the market by pioneering groundbreaking therapies for psychiatric and neurological disorders. Their commitment to developing first-in-class treatments reflects their mission to bring hope and reli...

Vistagen Therapeutics Inc Achieves Remarkable Financial Milestone with Revenue of $0.2777 Million in Q3 2023

Vistagen Therapeutics Inc, a late clinical-stage biopharmaceutical company based in South San Francisco, has recently reported its financial results for the most recent fiscal period. The company recorded a revenue of $0.2777 million during this period, compared to a deficit of $-17.483 million reported in the corresponding period last year. The net deficit for the recent period was $-6.588 million.
The positive change in financial performance indicates progress and improvement for Vistagen Therapeutics Inc. This could be attributed to various factors, such as successful clinical trials or the launch of new products in the market. The company's ability to reduce its overall deficit is a promising sign fo...

Vistagen Therapeutics Inc Successfully Narrows Deficit and Boosts Financial Performance Amidst Challenging Times

Vistagen Therapeutics Inc (VTGN) has recently released its financial results for the fiscal period closing June 30th, 2023, and the numbers are undoubtedly impressive. The company has managed to significantly reduce its loss per share compared to the previous year, showing a decrease from $-2.87 to $-0.94 per share. Additionally, the earnings per share have improved from $-1.71 in the prior quarter to the current value.
Despite the challenging economic conditions caused by the pandemic, VTGN has been able to maintain its revenue levels, with no significant changes reported compared to the same quarter a year ago. This stability is a remarkable achievement in itself, as many businesses have struggled to ...


Date modified: 2024-06-12T11:42:59+00:00





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com